Mercer Global Advisors Inc Halozyme Therapeutics, Inc. Transaction History

Mercer Global Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$37.81 - $52.4 $131,730 - $182,561	3,484 New	3,484 $182,000
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $131,045 - $222,131	-3,988 Reduced 29.53%	9,517 $363,000
Q4 2022 Feb 08, 2023	SELL	$40.06 - $59.44 $125,427 - $186,106	-3,131 Reduced 18.82%	13,505 $768,000
Q3 2022 Nov 15, 2022	SELL	$38.53 - $51.78 $87,039 - $116,971	-2,259 Reduced 11.96%	16,636 $658,000
Q2 2022 Aug 10, 2022	BUY	$37.35 - $48.3 $77,351 - $100,029	2,071 Added 12.31%	18,895 $831,000
Q1 2022 May 10, 2022	SELL	$31.97 - $41.06 $1.02 Million - $1.31 Million	-31,788 Reduced 65.39%	16,824 $671,000
Q4 2021 Feb 04, 2022	BUY	$31.82 - $40.75 $10,723 - $13,732	337 Added 0.7%	48,612 $1.96 Million
Q3 2021 Nov 10, 2021	BUY	$38.47 - $46.42 $419,323 - $505,978	10,900 Added 29.16%	48,275 $1.96 Million
Q2 2021 Aug 10, 2021	BUY	$38.84 - $51.31 $38,956 - $51,463	1,003 Added 2.76%	37,375 $1.7 Million
Q1 2021 May 11, 2021	BUY	$39.51 - $51.45 $1.44 Million - $1.87 Million	36,372 New	36,372 $1.52 Million

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.57B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.